The European Commission has granted marketing authorisation to Soliris (eculizumab) for expanded use in treating refractory generalized myasthenia gravis (gMG) in children and adolescents aged 6 to 17 years who are anti-acetylcholine receptor antibody-positive (Ab ). This makes the drug the first targeted therapy to be approved for paediatric patients ...